Below are the most recent publications written about "Cardiovascular Agents" by people in Profiles.
-
Jia X, Al Rifai M, Hussain A, Martin S, Agarwala A, Virani SS. Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well. Curr Atheroscler Rep. 2020 10 03; 22(12):72.
-
Marian AJ. Editorial: Overcoming current limitations of genetic testing in cardiovascular medicine. Curr Opin Cardiol. 2020 05; 35(3):187-190.
-
Fried JA, Ramasubbu K, Bhatt R, Topkara VK, Clerkin KJ, Horn E, Rabbani L, Brodie D, Jain SS, Kirtane AJ, Masoumi A, Takeda K, Kumaraiah D, Burkhoff D, Leon M, Schwartz A, Uriel N, Sayer G. The Variety of Cardiovascular Presentations of COVID-19. Circulation. 2020 06 09; 141(23):1930-1936.
-
Birnbaum Y. Introduction and Vision. Cardiovasc Drugs Ther. 2020 02; 34(1):1-2.
-
Safavi-Naeini P, Razavi M. Postural Orthostatic Tachycardia Syndrome. Tex Heart Inst J. 2020 02; 47(1):57-59.
-
Xie JX, Gunzburger EC, Kaun L, Plomondon ME, Barón AE, Waldo SW, Virani SS, Maddox TM, Mavromatis K. Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program. Circ Cardiovasc Qual Outcomes. 2019 11; 12(11):e005455.
-
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 11 21; 381(21):1995-2008.
-
Sudasena D, Balanescu DV, Donisan T, Hassan S, Palaskas N, Kim P, Karimzad K, Lopez-Mattei J, Arain S, Gould KL, Iliescu C. Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor Sorafenib. Cardiovasc Toxicol. 2019 08; 19(4):382-387.
-
Hoyt T, Feldman MD, Okutucu S, Lendel V, Marmagkiolis K, McIntosh V, Ates I, Kose G, Mego D, Paixao A, Iliescu C, Park J, Shaar M, Avci R, McElroy A, Dijkstra J, Milner TE, Cilingiroglu M. Assessment of Vascular Patency and Inflammation with Intravascular Optical Coherence Tomography in Patients with Superficial Femoral Artery Disease Treated with Zilver PTX Stents. Cardiovasc Revasc Med. 2020 01; 21(1):101-107.
-
Mills JL, Conte MS, Murad MH. Critical review and evidence implications of paclitaxel drug-eluting balloons and stents in peripheral artery disease. J Vasc Surg. 2019 Jul; 70(1):3-7.